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Techniques to induce the development of a new
arterial blood supply should allow limb salvage in
patients with severe arterial insufficiency and nonre-
constructable vessels. Several attempts to supply an
indirect source of arterial inflow via tissue transfer to
ischemic limbs have been reported.1-9 Although
these reports suggest that the transposition of a vas-
cularized tissue flap may result in neovascularization
of the ischemic recipient bed, the technique has not
been generally accepted because of a lack of long-
term success. 
Recently, the use of specific growth factors pro-
moting vascular development has been examined in
animal models of hind limb and myocardial
ischemia.6,10-14 Angiogenic growth factors that have
been shown to enhance vascular development
include basic fibroblast growth factor (bFGF),
endothelial cell growth factor (ECGF), and vascular
endothelial growth factor (VEGF). bFGF is a multi-
functional, heparin-binding growth factor that has
been isolated from a wide variety of tissue and tumor
sources and is known to be a potent endothelial cell
mitogen. bFGF is synthesized by endothelial cells
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Purpose: In a rabbit model, transposition of a muscle pedicle flap to an ischemic hind limb
has been shown to result in the development of new blood vessels that connect the arterial
circulation of the flap to the circulation of the limb. The hypothesis that exogenous recom-
binant basic fibroblast growth factor (bFGF) would enhance the development of this new
blood supply was examined and the regulation of bFGF in this process was investigated. 
Methods: The right common iliac artery was ligated in 12 male New Zealand white rab-
bits. An abdominal wall muscle flap based on the left inferior epigastric artery was trans-
posed to the right thigh. bFGF in phosphate-buffered saline (PBS) at 3 ng/h (n = 6),
or PBS alone (n = 6), was infused for 7 days via mini-osmotic pumps with an infusion
catheter positioned at the flap-muscle interface. The flap-muscle interface was immuno-
stained with anti-a –actin antibody to determine blood vessel density (number of ves-
sels/mm) and with anti-bFGF antibody to evaluate bFGF distribution. RNA was iso-
lated from these sections, and polymerase chain reaction (PCR) was used to examine
endogenous bFGF messenger RNA (mRNA) expression. 
Results: Blood vessel density was significantly increased in animals receiving exogenous
bFGF (22.0 ± 10.6 vessels/mm vs. 10.7 ± 8.8 vessels/mm, P = .009). In the controls,
neovessels were arranged in clusters with endogenous bFGF concentrated around these
clusters. In bFGF-treated animals, vessels were diffusely scattered throughout the flap-
limb interface, corresponding to the distribution pattern of infused bFGF. There was no
difference in bFGF mRNA expression between the control and the bFGF-treated groups. 
Conclusion: Exogenous bFGF infusion significantly augmented new blood vessel devel-
opment at the flap-limb interface. Endogenous bFGF was up-regulated around the
newly developed microvessels in control animals, and vessel growth correlated with the
diffuse distribution of exogenous bFGF, implicating bFGF as an important factor in
angiogenesis. Exogenous bFGF did not affect bFGF mRNA expression, suggesting that
the regulation of bFGF is not under autocrine control. (J Vasc Surg 1998;28:919-28.)
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and stored in the extracellular matrix in association
with heparan sulfate proteoglycans.15 This intimate
association with the extracellular matrix protects
bFGF from degradation16,17 and makes bFGF avail-
able during local proteolysis. bFGF has been
demonstrated to be important in the process of
angiogenesis, a necessary component of embryonic
development, wound repair, and tumor growth.18,19
Previous studies of ischemic limbs have docu-
mented the hypertrophy or recruitment of pre-exist-
ing (ie, collateral) vessels in response to bFGF,
ECGF, or VEGF, resulting in increased vessel densi-
ty in a limb distal to an arterial ligation.6,10-14
We used an established model of persistent hind
limb ischemia that is unique because it allows for the
study of newly developing blood vessels across a tis-
sue interface, rather than simply collateral develop-
ment.20 Enhancement of this process may lead to
treatment modalities for severely ischemic limbs in
which direct revascularization is not possible. The
hypothesis that exogenous bFGF will augment new
blood vessel growth was examined and the role of
bFGF in the control of new blood vessel develop-
ment was investigated.
MATERIALS AND METHODS
Animal model 
The model of chronic hind limb ischemia has
been described.20,21 This model has been shown to
consistently reduce resting hind limb perfusion to
30% of baseline for at least 7 days.21 When a well
perfused abdominal wall muscle flap is transposed to
the ischemic hind limb, new blood vessels that con-
nect the arteries of the flap with the native circula-
tion of the limb have been shown to develop; these
vessels have been demonstrated angiographically20
and histologically.22 These new vessels have been
shown to increase the resting perfusion of the
ischemic limb by 45%.20
The present study design was approved by the
Animal Use and Care Administrative Advisory
Committee of the University of California, Davis.
The guidelines of the National Institutes of Health
(publication number 86-23, “Guide for the Care
and Use of Laboratory Animals,” revised 1985)
were followed throughout the course of the study.
Twelve New Zealand white rabbits weighing 2.5 to
3.5 kg were anesthetized with an intramuscular
injection of 0.5 mg/kg acepromazine, 5 mg/kg
xylazine, and 75 mg/kg ketamine. The animals also
received 10 mg/kg enrofloxacin intramuscularly
prior to operation. An intravenous line for infusion
of normal saline was placed in a dorsal ear vein. Hind
limb blood pressure was determined using a pulse
sensor (RTBP096, Kent Scientific Corporation,
Litchfield, Conn). After occlusion of arterial flow
with a pediatric blood pressure cuff proximal to the
pulse sensor probe, the systolic arterial pressure was
determined to be the cuff pressure at which a pul-
satile waveform reappeared on a strip chart recorder
as the cuff was slowly released.
A midline laparotomy was performed using ster-
ile technique. The right common iliac artery was iso-
lated at its origin, ligated, and transected. Hind limb
blood pressure was measured both before and after
surgery to confirm arterial ligation. A muscle flap
based on the left deep inferior epigastric artery was
developed; the terminal arborization of this artery
determined the distal edge of the flap. The flaps mea-
sured 9.3 ± 0.8 cm by 2.1 ± 0.2 cm. The left epigas-
tric muscle flap was sutured to the anteromedial right
thigh (Fig 1). Mini-osmotic infusion pumps (Alza
model 2ML1, Alza Corp., Palo Alto, Calif) were
secured in the peritoneal cavity. A polyethylene
catheter (PE-60, Fisher Scientific, Santa Clara, Calif)
extended from the pump to the muscle-flap interface
on the right thigh. The abdominal muscles were
reapproximated at the midline after flap dissection. 
The mini-osmotic pumps delivered a solution at a
continuous rate of 10 m L/h for 7 days. Before
surgery, the animals were assigned to either the
experimental or the control group. The 6 experi-
mental animals had infusion, via the mini-osmotic
pumps, of recombinant human bFGF (Gibco-cat.
no. 13256-029, Grand Island, NY) in phosphate-
buffered saline (PBS) with 0.1% bovine serum albu-
min at a rate of 3 nanograms of bFGF per hour (10
m L/h) for 7 days (bFGF group). bFGF has been
shown to retain its biological activity when stored in
microcapsules at 37°C for up to 4 weeks.23 The 6
control animals had infusion of PBS with 0.1%
bovine serum albumin at 10 m L/h for 7 days (con-
trol group).
On day 7, all rabbits were clinically evaluated for
hind limb function and muscle atrophy. Function
was evaluated by observing the posture of the hind
limb at rest and during hopping. Muscle atrophy was
determined by measuring the thigh and calf circum-
ferences of both hind limbs. The animals were then
reanesthetized, and hind limb blood pressure was
measured. The rabbits were exsanguinated by a
catheter placed in the common carotid artery and
were killed with an overdose of ketamine and potas-
sium chloride. The pelvis and hind limb tissues were
perfusion fixed with 1000 ml of 10% buffered for-
malin, infused at a pressure of 100 mm Hg through
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a 14-gauge catheter placed in the infrarenal aorta. A
block of tissue, including the interface between the
muscle flap and underlying limb muscle with the
infusion catheter remaining in place, was harvested
and placed in 10% formalin solution.
Recombinant human bFGF 
The preparation of recombinant human basic
FGF was supplied as lyophilized powder. The bFGF
was reconstituted by means of 0.1% bovine serum
albumin in PBS, which had been filter-sterilized
through a 0.22 m m millipore filter. The infusion
pumps were loaded using sterile technique with 0.5
m g bFGF diluted to a volume of 2 ml with 0.1%
bovine serum albumin in PBS.
Blood vessel density. The harvested tissue blocks
were dehydrated through a graded series of alcohol
and then paraffin-embedded. Histologic sections (6
m m thick) perpendicular to the flap-limb muscle inter-
face were cut at 5 mm intervals. The sections were
immunostained for a -actin antibody. This antibody
recognizes only the a -actin isoform of smooth muscle
cells and does not react with striated cardiac or skele-
tal muscle cells. Anti-a –actin antibodies (Boehringer
Mannheim Biotechnology, Indianapolis, Ind) were
applied in a 1:200 dilution, and the sections were
stained using standard immunoperoxidase staining
procedure with a commercial kit (Vectastain, Vector
Laboratories, Burlingame, Calif) and counterstained
with hematoxylin and eosin. In our previous experi-
ence with this rabbit model, we found the more con-
ventional endothelial markers, factor VIII and various
lectins, to be very nonspecific.22 The most specific
immunostaining was achieved against a -actin.
After staining, the slides were examined, using
light microscopy, to determine microvascular densi-
ty. Histologic sections were cut 5 mm and 10 mm
from the end of the flap (near the placement of the
infusion catheter). Blood vessels were identified by
tubular morphology with a single layer of endothe-
lial cells, the presence of intraluminal red blood cells,
and positive a -actin staining.22 For each section, the
total number of new blood vessels in the interface
between the abdominal wall flap and the thigh mus-
cle was counted by 2 independent blinded observers
and normalized per linear distance of the flap-limb
interface (number of blood vessels/mm).
Distribution of bFGF. Immunoperoxidase
staining of the sections with antibodies specific to
bFGF was used to assess the expression of endoge-
nous bFGF and the radius of diffusion of the exoge-
nous growth factor. bFGF staining was correlated to
the location of enhanced angiogenesis. The primary
anti-bFGF-antibody (developed in chickens) was
donated by a private source (Dr J. Sasse, Tampa, Fla)
with secondary immunoperoxidase staining by stan-
dard techniques using a commercial kit (Vectastain,
Vector Laboratories, Burlingame, Calif).
bFGF mRNA expression. Polymerase chain
reaction (PCR) was used to examine the expression
of bFGF mRNA in the sections. Total RNA was iso-
lated from 25 sections (each 6 m m thick) using the
guanidine isothiocyanate method.24 The RNA was
phenol extracted and then ethanol precipitated with
transfer RNA (tRNA) as carrier. The resulting pellet
was dissolved in 30% formamide. The RNA was
probed for bFGF. The following primers were specif-
ic for sense bFGF: (5’ primer) 5’-AAG AGC GAT
CCG CAC ATC AA-3’ and (3’ primer) 5’-GGA
TAG CTT TCT GTC CAG GT-3’, and for b -actin:
(5’ primer) 5’-GTC GCC CTG GAC TTC GAG C-
3’ and (3’ primer) 5’-GGT ACA TGG TGG TGC
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Fig 1. Diagrammatic illustration of the surgical proce-
dure performed on the rabbits. A muscle flap based on the
left deep inferior epigastric artery is sutured onto muscle
of the right thigh after ligating the right common iliac
artery. (Courtesy of Pevec WC, Hendricks D, Rosenthal MS,
Shestak KC, Steed DL, Webster MW: Revascularization of
an ischemic limb by use of a muscle pedicle flap: A rabbit
model. J Vasc Surg 1991;13:385–90.) 
CGC CA-3’. bFGF mRNA was specifically amplified
utilizing primers that span intron/exon boundaries,
thus discriminating between mRNA and genomic
DNA amplification. Bovine brain RNA was used as a
positive control because it is a rich source of bFGF.25
Primers for b -actin, a protein expected to be present
in most, if not all, cell types in the tissue samples,
were used to normalize the amount of RNA between
samples. The band intensity was normalized by
adjusting the RNA concentration so all samples
amplified with the same efficiency. RNA from both
the control and the bFGF-treated groups was first
subjected to enzymatic digestion with either RNAse
or DNAse. The signal was identified by means of this
treatment as originating from mRNA and not from
contaminating genomic DNA. Equal amounts of
total RNA from the sections were reverse transcribed
to complementary DNA (cDNA) using 2.5 m mol of
random hexamers as primers. An aliquot of cDNA
from the reverse transcription reaction was used as
the template for the PCR reaction. The cDNA was
denatured by means of a 3 minute cycle at 97°C, fol-
lowed by 45 cycles of 1 minute at 94°C, 30 seconds
of annealing at 58°C, and 1.5 minutes extension at
72°C using a DNA thermal cycler (#480, Perkin-
Elmer Cetus, Branchburg, NJ). Twelve m l of the
PCR reaction were subjected to electrophoresis on a
2.5% agarose gel, and DNA was stained with ethidi-
um bromide and visualized with UV light.
Data analysis 
Values are reported as mean ± SD. Blood vessel
density was compared using the Mann-Whitney test
for the comparison of nonparametric data. Other
results were analyzed using a two-tailed Student’s t-
test for unpaired comparisons between 2 means. A P
value less than .05 was considered statistically signif-
icant. All calculations were performed using a com-
puterized statistical package (Abacus Concepts,
Berkeley, Calif.).
RESULTS
Clinical assessment 
On day 7, the animals were examined for evi-
dence of muscle atrophy. There was no difference in
body weight between the control group and bFGF-
treated group (Table I). Also on day 7, there were no
differences observed in either thigh or calf circumfer-
ence between the ischemic limb and the contralater-
al nonischemic limb in controls and bFGF-treated
animals. On day 0, blood pressure was undetectable
in the ischemic right hind limb in all animals, and it
remained undetectable on day 7, confirming arterial
ligation and limb ischemia for the duration of this
study. This is consistent with a previous study using
this animal model in which Hendricks et al. demon-
strated persistent hypotension in the experimental
limb, with only 2 of 20 animals having detectable
pulsatile arterial flow at 7 days postligation.21
Effects of local infusion of bFGF on blood vessel
density 
Local infusion of bFGF at 3 ng/h for 7 days
resulted in increased blood vessel density at the flap-
muscle interface. An average of 22.0 ± 10.6 ves-
sels/mm were seen in the bFGF-treated animals,
compared with 10.7 ± 8.8 in the controls (P = .009)
(Fig 2). The sections examined were within 3 to 5
mm from the end of the osmotic pump delivery
catheter, where the concentration of growth factor
would be expected to be the highest. In control sec-
tions, the new microvessels were observed to devel-
op in clusters, with other areas in the muscle-flap
interface relatively devoid of the new vessels (Fig 3).
In comparison, the microvessels developed in a more
random, diffuse pattern throughout the interface in
the bFGF-treated sections. The blood vessels
observed at the flap-muscle interface were more
mature than capillaries as they stained with antibod-
ies to a -actin, a smooth muscle cell protein.
Distribution of bFGF 
Staining with the anti-bFGF antibody showed
diffuse extracellular staining throughout the muscle-
flap interface of animals given the exogenous bFGF
as compared with control animals, confirming that
exogenous bFGF was being delivered to the area of
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Fig 2. Microvessel density at the muscle flap-hind limb
interface.
interest (Fig 4). Sections 5 to 10 mm distal to the
infusion catheter demonstrated little or no interface
staining, suggesting that exogenous bFGF did not
diffuse far from the catheter (data not shown). In
contrast, sections from the muscle-flap interface of
control animals demonstrated extracellular bFGF
only surrounding clusters of microvessels, with min-
imal extracellular staining elsewhere throughout the
interface. In both control and experimental animals,
bFGF was seen within the nuclei of endothelial cells.
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Table I. Comparison of physiologic parameters between rabbits in control and bFGF-treated groups.
Control bFGF-treated
(n = 6) (n = 6) P
Day 0
Weight (kg) 2.9 ± 0.3 2.9 ± 0.3 .78
Thigh circumference (cm) L 13.7 ± 1.2 13.6 ± 1.2 .91
R 13.6 ± 1.3 14.0 ± 1.3 .65
Calf circumference (cm) L 10.1 ± 0.9 10.3 ± 0.8 .63
R 10.1 ± 1.3 10.7 ± 1.3 .46
Preoperative BP (mm Hg) L 58 ± 8 60 ± 7 .66
R 55 ± 4 61 ± 10 .23
Postoperative BP (mm Hg) L 42 ± 21 50 ± 15 .49
R 0 0 —
Day 7
Weight (kg) 2.9 ± 0.2 2.9 ± 0.3 .87
Thigh circumference (cm) L 13.6 ± 1.0 13.8 ± 0.5 .79
R 13.6 ± 1.0 13.8 ± 0.9 .68
Calf circumference (cm) L 10.2 ± 1.2 10.2 ± 1.0 .90
R 10.1 ± 0.9 9.9 ± 1.1 .76
BP (mm Hg) L 47 ± 6 47 ± 9 .97
R 0 0 —
BP, Blood pressure
Fig 3. Histology of vessel density in the muscle-flap region of control and bFGF-treated ani-
mals. A, The flap-limb interface of a control animal, 50· magnification (hematoxylin and eosin
stain). Microvessels can be seen, but are scarce and arranged in clusters. B, The flap-limb inter-
face of a bFGF-treated animal, 50· magnification (hematoxylin-eosin stain). The distribution
pattern of microvessels is diffuse, and vessel density is increased.
FPO FPO
Expression of bFGF mRNA
PCR was performed to determine whether the
addition of exogenous bFGF affected the expression of
endogenous rabbit bFGF mRNA. A single amplified
product of 273 base pair (bp) was detected, which cor-
responds to endogenous rabbit bFGF mRNA (Fig 5).
The PCR product’s identity was confirmed by means
of DNA sequencing (data not shown). The amplified
product was caused specifically by bFGF mRNA and
not contaminating genomic DNA, because the treat-
ment of the samples before reverse transcription with
RNAse destroyed the signal, and DNAse treatment
did not affect the signal. Endogenous bFGF mRNA
expression was detected in both the control animals
and those treated with exogenous bFGF. No differ-
ences in expression were detected. The similar intensi-
ty of the b -actin signals indicate that equivalent
amounts of RNA were tested in both the control and
the bFGF-treated PCR reactions. Bovine brain was
used as a positive control because of the known high
endogenous bFGF concentration.
DISCUSSION
A previously developed rabbit model of hind limb
ischemia was used to examine the effects of exoge-
nous bFGF on the development of new blood vessels
between a well-perfused muscle flap and ischemic
limb muscle.20 An animal model of reproducible,
persistent limb ischemia is necessary for studying
angiogenesis in ischemic skeletal muscle. Common
iliac artery division in the rabbit has been shown to
produce immediate limb ischemia with a decrease in
resting hind limb perfusion to 31% of baseline, which
persists for 7 days and has been documented by radi-
olabled microsphere studies.20,21 By postligation day
17, microsphere measurements show recovery of the
perfusion to 80% of baseline. Thus, for at least 7 days,
this model provides profound hind limb ischemia.
Contrast injected into the artery of the flap was
shown by means of angiography to opacify the native
hind limb vasculature, confirming that connections
had developed between the arteries of the flap and
the circulation of the limb. By means of microsphere
measurements, these new arterial connections were
demonstrated to be hemodynamically significant,
increasing resting muscle perfusion by 45%.20
Histologic confirmation of microvessel development
at the interface between the flap and the ischemic
limb was documented in a subsequent report.22 The
vessels could be detected at 7 days, but not 3 days,
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Fig 4. Immunohistochemical staining for bFGF at the muscle-flap interface in control and
bFGF-treated animals. A, Control tissue, 40· magnification, showing intense pericellular stain-
ing with minimal staining in the muscle-flap interface. Brown stain indicates positive reaction
for bFGF. B, bFGF-treated tissue, 40· magnification, has both pericellular staining and diffuse
extracellular staining throughout the flap-limb interface.
FPO FPO
suggesting these were newly developed vessels. Also,
the vessels stained for proliferating cell nuclear anti-
gen (PCNA), which binds only to nuclei of prolifer-
ating cells, establishing that these were neovessels.
Thus, this is a unique in vivo model for studying new
blood vessels that develop across a tissue interface
where no vessels had previously existed.
bFGF is a cationic, 18 to 23 kd, 154 amino acid
polypeptide, first localized in 1974, and known to
be mitogenic for vascular endothelial cells.26-28 The
molecular mechanisms responsible for this mito-
genic effect have not been completely defined.
bFGF is widely distributed in the body and is syn-
thesized in considerable amounts by endothelial
cells.29 It is not secreted via the normal cellular
secretory pathways, as it lacks the necessary signal
peptide sequence. The biologic half-life of bFGF is
only a few minutes in vivo.30 It is bound in an inac-
tive state to glycosaminoglycans, mainly heparan sul-
fate, in the basement membrane and subendothelial
cell extracellular matrix.31,32 This “stored” growth
factor is available for rapid mobilization during
endothelial cell injury.33 There is evidence suggest-
ing that ischemia stimulates the release of various
angiogenic agents, including bFGF.34,35
Angiogenesis is necessary not only for normal
growth and development, but also for tissue repair
and wound healing. Angiogenesis is initiated in both
acute and chronic conditions. Tissue injury leads to
hypoxia, which has been suggested as a powerful
stimulus for angiogenesis.14,26 Hypoxia has also
been shown to induce expression of VEGF, another
potent angiogenic growth factor.37 Clinical studies
of patients with proliferative diabetic retinopathy
have demonstrated the effects of ischemia on local-
ized neovascularization, as well as the potent effect
of bFGF on retinal endothelial mitosis.36 The for-
mation of new blood vessels involves the interaction
of many basic cellular activities, including capillary
basement membrane destruction and endothelial
cell migration, division, and organization into tubu-
lar structures. 18
Previous animal studies of hind limb ischemia
have demonstrated enhanced collateral artery devel-
opment with the intramuscular or intravascular
administration of angiogenic growth factors:
bFGF,11 ECGF,10 and VEGF.12,13 Repeated intra-
muscular administration of bFGF11 and intramuscu-
lar and intravascular administration of VEGF13 has
been shown to increase collateral arterial develop-
ment in experimental models of hind limb ischemia
created by iliac artery ligation. Neovascularization
has also been described in models of chronic
myocardial ischemia exposed to bFGF.6,14 In pilot
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Fig 5. Actin and bFGF mRNA expression analyzed by PCR. Lane 1—DNA marker; control
animal, lanes 2–5: lane 2—positive control, lane 3—DNAse treated, lane 4—RNAse treated,
lane 5—negative control; bFGF-treated animal, lanes 6–9: lane 6—positive control, lane 7—
DNAse treated, lane 8—RNAse treated, lane 9—negative control; lane 10—bovine brain. The
primer pair used is shown above each panel. Arrow indicates position of correct PCR fragment.
experiments for this study, bFGF was systemically
infused via the jugular vein. After 1 week, there was
no difference in vessel density (data not shown).
This result was not surprising, given bFGF’s avidity
for binding to extracellular matrix proteins and
endothelial receptors. It would be expected that
massive systemic doses would be required to over-
come the nonspecific binding to extracellular matrix
proteins to see a local effect. In other pilot studies,
systemic and local infusions of VEGF resulted in no
enhanced angiogenesis. Although this may have
been caused by an improper dose of VEGF, a species
effect with the isoform used, or another technical
reason, the dramatic response to local infusion of
bFGF led to its use in the current study.
Because of bFGF’s avidity for binding to extra-
cellular matrix proteins and to widely distributed
receptors and its short biologic half-life in the pres-
ence of proteases, it would be expected that a pro-
longed local effect would require either repeated
local injections or a continuous local infusion. This
was the rationale for delivering bFGF to the flap-
limb interface via a local infusion pump. Edelman et
al23 showed that bFGF retained biologic activity
when protected in microcapsules at 37°C for 4
weeks. Mayer et al,38 Cuevas et al,39 and Epply et
al40 showed angiogenic activity was increased by
bFGF when infused via mini-osmotic pumps for 7 to
28 days. 
Neovascularization of ischemic tissue occurred in
this model. Local infusion of exogenous bFGF, at a
dose of 3 ng/h for 7 days, significantly augmented
new blood vessel development between an indepen-
dently perfused muscle pedicle flap and ischemic
skeletal muscle. This dose for bFGF administration
was based on other studies of local infusions of
bFGF.14,38,39 A 7-day experiment was chosen
because this model has been documented to produce
hind limb ischemia for at least 7 days.21 bFGF is an
“early” growth factor. Prior work with this model
showed no histologic microvessels at 3 days, but
mature microvessels, with smooth muscle cells in the
media and positive staining for proliferating cell
nuclear antigen, at 7 days.22 Ibukiyama showed the
peak of angiogenesis with exogenous bFGF occurred
within 1 week after administration.41 Thus, a 7-day
model was considered to be most appropriate.
bFGF is a known mitogen and chemoattractant
for endothelial cells.18,42 Further, bFGF and hypox-
ia have been shown to synergistically increase mRNA
for VEGF, a potent angiogenic factor, in rabbit vas-
cular smooth muscle cells.43 A new vascular system
has been shown to develop between host and graft
in skeletal muscle implanted into the cheek pouch of
a hamster.44 These vessels grew from the graft to the
host and functioned in 4 days. It is speculated that
the addition of bFGF increases the intrinsic response
of new microvessels budding to bridge the gap
between the perfused muscle flap and the ischemic
hind-limb muscle.
Angiogenesis was documented in all animals by
means of direct histologic evidence of new blood ves-
sel development. Exogenous bFGF doubled the
microvessel density at the flap-limb interface, with the
new blood vessels dispersed randomly throughout the
interface. In contrast, sections from the control group
had only isolated clusters of microvessels. This type of
heterogenous angiogenesis is similar to that described
by Weidner and Folkman in their studies of breast car-
cinoma, in which neovascular “hot spots” were asso-
ciated with metastatic foci.45,46 The processes respon-
sible for cluster formation are not understood and are
not addressed in this study. However, this is currently
an area of active investigation.
Immunostaining confirmed that bFGF was deliv-
ered to the flap-limb interface, and that it diffused
only a short distance (5 to 10 mm) from the tip of
the infusion catheter. The extracellular matrix dif-
fusely stained for bFGF to a distance 5 to 10 mm
from the catheter tip; large numbers of new
microvessels were diffusely distributed in this same
region (Fig 4, B). In contrast, fewer new microves-
sels developed in the control animals, and these ves-
sels developed in inhomogeneous clusters. In con-
trol animals, bFGF stained only in the vicinity of
these clusters of microvessels (Fig 4, A). Although
there is no specific antibody to distinguish exoge-
nous from endogenous bFGF, these findings
(increased numbers of microvessels in the region of
exogenously supplied bFGF) strongly suggest that
exogenous bFGF enhanced angiogenesis.
Similar endogenous bFGF mRNA expression was
found in both the control animals and the bFGF-
treated animals. This suggests that the expression of
the endogenous bFGF was not regulated in an
autocrine fashion. If bFGF is regulated in either a pos-
itive or negative autocrine manner, variances in bFGF
mRNA expression should be observed in bFGF-treat-
ed samples. Perhaps bFGF expression is regulated by
an alternative growth factor or cytokine induced by
ischemia. Because of the semiquantitative nature of
the PCR performed in this study, the amount of
mRNA cannot be quantified. Further studies using
in-situ hybridization are needed to identify and quan-
titate the specific cells expressing the angiogenic
growth factor in the muscle-flap interface of this
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model. Also planned is infusion of antibodies to bFGF
receptors. A decrease in angiogenesis in response to
such antibodies would be compelling evidence of the
central role of bFGF in angiogenesis in this model. 
The physiologic relevance of the new blood ves-
sels induced was not addressed. However, previous
microsphere perfusion determinations demonstrated
that resting limb perfusion was increased by 45%,
presumably via the vascular connections between the
flap and the ischemic limb.20 If the dose and area of
distribution of bFGF can be increased, a greater
angiogenic response that may have a more signifi-
cant physiologic effect can be expected. In addition,
physiologic and long-term data are required to
assess whether the enhanced angiogenesis in this
model represents a persistent, functioning, new vas-
cular system, or simply a temporary, non-functional,
neovascular response.
CONCLUSIONS
Local infusion of exogenous bFGF, a potent
angiogenic mitogen, significantly increased new
blood vessel development. Immunostaining con-
firmed that bFGF was delivered to the muscle-flap
interface. In the bFGF-treated group, the pattern of
vessel development correlated with the diffusion of
bFGF. bFGF mRNA expression was not downregu-
lated after exogenous bFGF infusion. In-situ
hybridization studies to quantitate and localize
endogenous bFGF production are in progress, as are
assays for bFGF receptors. These studies should fur-
ther define the role of bFGF in the control of new
blood vessel ingrowth into ischemic skeletal muscle.
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